Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 injection vs tolvaptan tablets in congestive heart failure
jRCT2080224173Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tolvaptan sodium phosphate in heart failure (HF) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change in body weight from baseline to Day 5. Started Dec 2018; status: completed.
02
Drugs
tolvaptan sodium phosphate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT2080224173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224173.